Amgen (NASDAQ: AMGN) is a biotechnology firm engaged in the discovery and manufacture of human therapeutics. It markets products in the areas of supportive cancer care, nephrology, inflammation, and metabolic diseases. Principal offerings include anemia treatments Aranesp and Epogen, rheumatoid arthritis drug Enbrel, and white blood cell stimulator Neupogen. Amgen has marketing alliances with Hoffmann-La Roche and Kirin. Baxter International (NYSE: BAX), Johnson & Johnson (NYSE: JNJ) and Novartis (NYSE: NVS) and major competitors.
The company pleased the Street late last month, when it announced Phase 3 trial results showing that its experimental osteoporosis drug significantly reduced the risk of bone fractures in post-menopausal women. As well, the firm reported Q2 EPS of $1.14 and revenues of $3.76 billion. Both measures topped consensus Street estimates ($1.02, $3.58 billion). Management also guided FY08 EPS to $4.25-$4.45 ($4.19 consensus) and FY08 revenues to $14.6-$14.9 billion ($14.42B consensus). Eight brokerages subsequently declared AMGN a "buy" and issued price targets in the range $67-$80.
As the second quarter earnings crunch begins in earnest this week, the bear market has investors jittery and prognosticators spinning out dire warnings. In the wake of mixed results from Alcoa (NYSE: AA) and General Electric (NYSE: GE) kicking things off last week, here's a look at what Wall Street is expecting from many of the companies scheduled to report this coming week.
Analysts surveyed by Thomson Financial are expecting the following companies to report a rise in earnings when compared to the same period of the previous year.
Nucor Corp. (NYSE: NUE): $1.80 EPS (36.6%) on sales of $6.4 billion (+53.0%)
Google Inc. (NASDAQ: GOOG): $4.74 EPS (24.9%) on sales of $3.9 billion (+41.6%)
Nokia Corp. (NYSE: NOK): 56 cents EPS (23.2%) on sales of $19.9 billion (+17.8%)
CSX Corp. (NYSE: CSX): 90 cents EPS (21.1%) on sales of $2.9 billion (+12.8%)
Altera Corp. (NASDAQ: ALTR): 27 cents EPS (18.5%) on sales of $346.7 million (+8.4%)
IBM (NYSE: IBM): $1.82 EPS (+17.6%) on sales of $25.9 billion (+9.0%)
eBay Inc. (NASDAQ: EBAY): 41 cents EPS (17.1%) on sales of $2.2 billion (+18.0%)
Edwards Lifesciences Corporation (NYSE: EW) provides products and technologies designed to treat cardiovascular diseases. Offerings include tissue heart valves, valve repair products, heart monitoring equipment, central venous access devices and cardiac surgery system products. The company sells its goods through a direct sales force and independent distributors worldwide. Formerly part of Baxter International (NYSE: BAX), the firm was a year 2000 spin-off.
Edwards surprised the Street late last month, when it reported Q1 EPS of 56 cents and revenues of $296.8 million. Analysts had been expecting 49 cents and $284.4 million. In discussing the results, the CEO noted the success of new products and strong international sales growth. Management also guided Q2 EPS to 62-66 cents (58 cent consensus), FY08 EPS to $2.45-$2.53 ($2.35 consensus) and FY08 revenues to $1.210-$1.260 billion ($1.18B consensus).
The blood thinner Heparin, used for surgery and dialysis has now killed 81 people in the US. According toThe New York Times, "The F.D.A. has identified 12 Chinese companies that have supplied contaminated heparin to 11 countries." The contamination that caused the problems appears to come from manufacturers in China.
The news reopens the question of who is at fault when China ships bad products to the US. Companies like Mattel (NYSE: MAT) and Baxter (NYSE: BAX), a big heparin supplier, would like to blame the Chinese. Alternatively, they could say that the FDA does not have enough inspectors to keep up with drug components imported from the big Asian country.
But all of that is a dodge. Any company that sells a product should ultimately be responsible for that product's safety no matter what the current law says. Baxter makes the money on heparin, why should another entity be responsible for making sure its is safe?
Baxter might argue that it cannot sell heparin at a profit if all of the inspection responsibility falls to it. If so, it should exit the business and leave it to a company that can. All of those people who died would probably agree.
This year, the International Trade Commission is set to issue rulings on whether Samsung and Nokia Corporation (NYSE: NOK) have infringed patents from InterDigital Inc (NASDAQ: IDCC). If InterDigital, who licenses its patents to iPhone maker Apple Inc (NASDAQ: AAPL), wins, fees from the deals could double its revenue over the next few years, the Wall Street Journal contended.
According to FDA commissioners, the New York Times reported that Baxter International Inc's (NYSE: BAX) critical blood thinner heparin, which has been linked to nearly 20 deaths and whose base was created in China, contained a "possibly counterfeit" ingredient that "mimicked the real drug."
In his opening arguments in the state of Alaska's lawsuit against Eli Lilly & Company (NYSE: LLY), an attorney for the state alleged the drug maker failed to warn doctors and patients of dangerous side effects associated with its drug Zyprexa, the Associated Press reported.
The Wall Street Journal reported that the focus of reports of four deaths and 350 allergic reactions to Baxter International Inc's (NYSE: BAX) generic version of the blood thinner drug Heparin, and the ingredients supplied by a Chinese manufacturer, also includes Wisconsin-based Scientific Protein Laboratories, a co-owner of the Chinese manufacturing plant, and majority owned by American Capital Strategies Ltd (NASDAQ: ACAS), a Maryland buyout firm.
Citigroup Incorporated (NYSE: C) has suspended investors at its CSO Partners hedge fund from withdrawing their money after they attempted to pull more than 30% of the fund's nearly $500M in assets, the Wall Street Journal reported.
AT&T Inc (NYSE: T) is seeking more revenue from India as it tries to expand its consumer mobile phone operations outside the U.S, the Financial Times reported.
OTHER PAPERS:
According to the New York Times, the FDA broke its own rules by approving for sale Baxter International's Heparin without first inspecting a Chinese plant where the drug's key ingredient is made.
Marriott International Inc. (NYSE: MAR) fourth quarter earnings fell 20% to $176 million or 46 cents per share, as it took a hit from the closure of its business making cleaner burning coal for tax credits. The company posted revenue of $4.1 billion. Excluding the loss from the discontinued operations, Marriott says it earned $236 million, or 62 cents per share, beating the 62 cents expected by analysts.
UBS AG (NYSE: UBS) on Thursday posted a fourth-quarter net loss -- the first since 1997 -- of $11.28 billion, and a loss for the entire year, due to investments in U.S. subprime mortgages. It said it expected more problems in 2008. The results were inline with previous guidance. UBS shares are down some 5.75% in premarket trading.
Boeing Co. (NYSE: BA) said Thursday it created a joint venture to be formed by June with Tata Industries Ltd. to make more than $500 million in aerospace components.
Taser International Inc. (NASDAQ: TASR) reported that fourth-quarter earnings doubled, reaching $4.7 million, or 7 cents a share, on 61% higher revenue. Sales rose to $31 million. Analysts polled by Thomson Financial expected a profit of 7 cents per share on $29 million of sales.
The active ingredient in Baxter International Inc's (NYSE: BAX) generic version of the anticlotting drug heparin, under investigation for four deaths and hundreds of bad reactions, was made in China, the Wall Street Journal reported.
Mike Zafirovski, CEO of Nortel Networks Corporation (NYSE: NT), said the company would examine possible opportunities to be taken over "when they arise." Mr. Zafirovski did not comment on rumors of a Motorola Inc (NYSE: MOT) merger, Reuters reported.
A plant in China may be producing flawed ingredients for the big-selling Baxter International (NYSE:BAX) blood thinner Heparin. According toThe Wall Street Journal, it is the same "blood-thinner that is under investigation after reports of hundreds of allergic reactions and four deaths among the drug's users."
While the FDA failed to inspect that facility, it is Baxter's responsibility to ensure the safety of its own products. The debacle is not unlike the one that plagued Mattel (NYSE: MAT) last year when it was importing toys from China that contained high levels of lead. In Baxter's case, however, it appears that people have lost lives.
Baxter and the FDA now probably face months of criticism, much of it coming from Congress, which is already concerned about the quality of China-made products.
Baxter also needs to worry about whether it will be viewed as having any liability in the cases where Heparin caused illness. It looks like a trial lawyer's dream.
MOST NOTEWORTHY: Amag Pharmaceuticals, Corn Products and Alpharma were today's noteworthy initiations:
Baird initiated Amag Pharmaceuticals (NASDAQ: AMAG) with an Outperform rating and believes concerns regarding ferumoxytol approvability are misplaced.
JP Morgan assumed coverage of Corn Products (NYSE: CPO) with an Overweight rating and points to the company's growth in emerging markets and improved business economics in its core U.S. market.
RBC Capital is positive on Alpharma's (NYSE: ALO) Flector opportunity in the U.S. topical NSAID market. The firm started shares with an Outperform rating and $28 target.
OTHER INITIATIONS:
Merrill resumed coverage of Baxter (NYSE: BAX) with a Buy rating.
Goldman initiated Teradyne (NYSE: TER) with a Neutral rating and $11 target.
Allianz AG (NYSE: AZ) was initiated with a Buy rating at Societe Generale.
In the business world, innvoation leads to longevity. There is a medical products firm in Deerfield, Illinois that was the first manufacturer of commercially prepared intravenous solutions. It was also responsible for such landmark developments as the first container that could store blood for more than a few hours, the first means of separating plasma from whole blood and storing it for future use, and the first disposable total-bypass blood-oxygenator. The company has been in business for 76 years.
Baxter International (NYSE: BAX) is a diversified medical products and services company. It provides devices, pharmaceuticals, and biotechnology for the treatment of hemophilia, immune disorders, cancer, infectious diseases, kidney disease and trauma. The BioScience segment manufactures plasma-based therapies for immune disorders, biosurgery products for hemostasis, and vaccines. The Medication Delivery unit makes intravenous solutions and administration sets. The Renal segment manufactures products for peritoneal dialysis, a home therapy for people with end-stage renal disease. Boston Scientific (NYSEL: BSX) is a major competitor.
Investors were pleased last week, when Citigroup upgraded the shares from "hold" to "buy." Analyst Matthew J. Dodds said the firm can increase its gross margins above Wall Street expectations, a welcome prediction ahead of the Baxter's fourth quarter report (1/24). He also predicted 2008 EPS of $3.21, versus the Street expectation of $3.10.
In biotechnology, corporate success is a function of approved drugs, pipeline activity and positive cash flow. By those standards, one of the most successful firms in the industry is a 27 year old Thousand Oaks, California outfit that was among the first developers of blockbuster biopharmaceuticals.
Amgen (NASDAQ: AMGN) is a biotechnology firm engaged in the discovery and manufacture of human therapeutics. It markets products in the areas of supportive cancer care, nephrology, inflammation, and oncology. Principal offerings include anemia treatments Aranesp and Epogen, rheumatoid arthritis drug Enbrel, and white blood cell stimulator Neupogen. Amgen has marketing alliances with Hoffmann-La Roche and Kirin. Competitors include Baxter International (NYSE: BAX), Johnson & Johnson (NYSE: JNJ) and Novartis (NYSE: NVS).
The company pleased the Street earlier in the week, when it said it expected 2007 adjusted EPS of close to $4.30. That was above the firm's previous guidance range ($4.13-4.23) and the consensus analyst view ($4.24). Management also announced that it plans to move ten molecules into mid-stage trials this year.
In the business world, innovation leads to longevity. There is a medical products firm in Deerfield, Illinois, that was the first manufacturer of commercially prepared intravenous solutions. It was also responsible for such landmark developments as the first container that could store blood for more than a few hours, the first means of separating plasma from whole blood and storing it for future use, and the first disposable total-bypass blood-oxygenator. The company has been in business for 76 years.
Baxter International (NYSE: BAX) is a diversified medical products and services firm. It provides devices, pharmaceuticals, and biotechnology for the treatment of hemophilia, immune disorders, cancer, infectious diseases, kidney disease and trauma. The BioScience segment manufactures plasma-based therapies for immune disorders, biosurgery products for hemostasis, and vaccines. The Medication Delivery unit makes intravenous solutions and administration sets. The Renal segment manufactures products for peritoneal dialysis, a home therapy for people with end-stage renal disease. The company has more than 250 facilities in 50 countries around the world. Boston Scientific (NYSE: BSX) is a major competitor.
In biotechnology, corporate success is a function of approved drugs, pipeline activity and positive cash flow. By those standards, one of the most successful firms in the industry is a 27-year-old Thousand Oaks, California outfit that was among the first developers of blockbuster biopharmaceuticals.
Amgen (NASDAQ: AMGN) is a biotechnology firm engaged in the discovery and manufacture of human therapeutics. It markets products in the areas of supportive cancer care, nephrology, inflammation, and oncology. Principal offerings include anemia treatments Aranesp and Epogen, rheumatoid arthritis drug Enbrel, and white blood cell stimulator Neupogen. Amgen has marketing alliances with Hoffmann-La Roche and Kirin. Competitors include Baxter International (NYSE: BAX) and Novartis (NYSE: NVS).
The stock popped last month on word an FDA advisory panel had rejected a proposal to set a specific target for red blood-cell levels in kidney-failure patients being treated with Aranesp, Epogen and Procrit. The latter is manufactured by Amgen, but sold by Johnson & Johnson (NYSE: JNJ). The panel's decision, if accepted by the FDA, could boost sales of the medications. Since the initial gain, the AMGN share price has been defining a bullish "flag" consolidation pattern. Prices frequently exit flags moving in the same direction they were traveling when they entered them. In this case, that would be to the upside.
Brokers recommend the stock with six "strong buys," six "buys," 18 "holds" and one "sell." The AMGN P/E ratio (16.19), PEG ratio (1.50), Price to Book ratio (3.73), Price to Cash Flow ratio (12.07), Price to Free Cash Flow ratio (16.98), Operating Margin (32.57%), Net Profit Margin (27.35%), Return on Assets (12.65%), Return on Investment (15.02%), Return on Equity (24.41%) and Net Income per Employee ($203.25k) compare favorably with industry, sector and S&P 500 averages. Institutions hold about 76% of the outstanding shares. The stock is one of those used to calculate the S&P 100, S&P 500 and Nasdaq 100 Indexes. Over the past 52 weeks, it has traded between $48.30 and $77. A stop-loss of $48.65 looks good here. Note that the firm is expected to release third quarter results on October 25, after the close.
On last night's "MAD MONEY" on CNBC, Jim Cramer wanted to show defensive stocks in the medical industrial field. He has seen enough earnings from big companies and he is fed up with the Fed sitting around while the U.S. economy is slowing to a halt. He wants an "Ultimate Defensive Portfolio" of three stocks that are defensive but whose businesses are still growing. He even wanted to take out the companies that are only growing because of foreign business.
1) Bard (C.R.) (NYSE: BCR) is one stock he's been behind since 2005, and he is still behind it. Besides thinking it can still be bought, there is more to like on it, especially its catheter business, but its biopsy technology and the angioplasty operations as well.
2) Becton, Dickinson (NYSE: BDX) is a safe traditional medical device and diagnostics company. BDX has been up 31% since Cramer first recommended it, and he thinks it will go higher. More on BDX here.
3) Baxter International Inc. (NYSE: BAX) was Cramer's #3 spot as the best of breed, but he only wants to buy it now if it sells off. You can read what else he noted on it.
Back in February I came up with a list of 20 Defensive Stocks for a Crummy Market. After those 20 stocks, I even came up with a list of 15 Second Line Defensive Stocks. Many of my names were different than Cramer's names at the time. Some of my picks were medical and some were not, and most were chosen at a time that fear and panic were starting to come front and center. These picks that Cramer came up with are all different in that they may grow, and not only because of the weak dollar.
Jon Ogg is a partner at 24.7 Wall St.; he does not own securities in the companies he covers.
a biotechnology firm engaged in the discovery and manufacture of human therapeutics. It markets products in the areas of supportive cancer care, nephrology, inflammation, and metabolic diseases. Principal offerings include anemia treatments Aranesp and Epogen, rheumatoid arthritis drug Enbrel, and white blood cell stimulator Neupogen. Amgen has marketing alliances with Hoffmann-La Roche and Kirin. Baxter International (NYSE: BAX), Johnson & Johnson (NYSE: JNJ) and Novartis (NYSE: NVS) and major competitors.
As the second quarter earnings crunch begins in earnest this week, the bear market has investors jittery and prognosticators spinning out dire warnings. In the wake of mixed results from 
.gif){kind=logo}
.gif){kind=logo}
Marriott International Inc. (NYSE: 
levels in kidney-failure patients being treated with Aranesp, Epogen and Procrit. The latter is manufactured by Amgen, but sold by 
Before the Bell: Stocks poised to rally on $125 billion bank investment plan
The Wal-Mart Weekly: Retailer accused of sweatshop conditions in Bangladesh
Fog clearing - maybe. Clear skies - no! GE, JNJ, MRK, PG, RTN, WFC
